MINDACT试验中70基因签名超低风险患者的结局
在MINDACT随机III期试验的6693例患者中,1000例(15%)为70基因签名超低风险。中位随访8.7年,超低风险患者8年无远处转移间期(DMFI)为97.0%,8年乳腺癌特异性生存(BCSS)为99.6%,预后优于低风险患者,作者认为这些患者可考虑进一步降阶梯治疗以避免过度治疗。
要点
- 超低风险患者8年DMFI为97.0%,8年BCSS为99.6%。
- 超低风险 vs 低风险调整后DMFI的HR为0.65(95%CI 0.45-0.94)。
- 作者认为超低风险患者可考虑进一步降阶梯治疗以避免过度治疗。
核心结论
- 70基因签名超低风险患者预后最佳,区别于低风险,8年BCSS超过99%,8年DMFI为97%。
- 作者认为这些患者可考虑进一步降阶梯治疗,以避免过度治疗和副作用风险。
研究设计与样本
- EORTC-10041/BIG-3-04随机III期MINDACT试验,纳入6693例患者,其中1000例(15%)为70基因签名超低风险。
- 按70基因签名结果(高、低、超低)分层,采用Kaplan-Meier分析和Cox回归风险比(95%CI)评估DMFI和BCSS。
主要发现
- 中位随访8.7年。
- 超低风险患者(n=1000)中67%年龄>50岁,81%肿瘤≤2 cm,80%淋巴结阴性,96%为1或2级肿瘤,99%为雌激素受体(ER)阳性。
- 84%患者接受全身治疗(69%内分泌治疗,14%内分泌治疗加化疗,1%其他),16%未接受辅助全身治疗。
- 超低风险患者8年DMFI为97.0%(95%CI 95.8-98.1),较低风险患者(n=3295,94.5%[95%CI 93.6-95.3])高2.5%。
- 调整临床病理和治疗特征后,超低风险 vs 低风险的DMFI风险比(HR)为0.65(95%CI 0.45-0.94)。
关键数值与推荐
- 超低风险患者8年DMFI为97.0%(95%CI 95.8-98.1)。
- 超低风险患者8年BCSS为99.6%(95%CI 99.1-100)。
- 超低风险 vs 低风险调整后DMFI的HR为0.65(95%CI 0.45-0.94)。
临床怎么用
- 作者认为超低风险70基因签名患者可考虑进一步降阶梯治疗,以避免过度治疗和副作用风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with 70-gene signature ultralow-risk breast cancers have shown excellent survival in historic cohorts, including randomized trials. The ultralow-risk subgroup was characterized to help avoid overtreatment. We evaluated outcomes of ultralow-risk patients in the largest cohort to date. METHODS: Of the 6,693 patients enrolled in the EORTC-10041/BIG-3-04 randomized phase III MINDACT trial, profiling revealed an ultralow-risk 70-gene signature in 1,000 patients (15%). Distant metastasis-free interval (DMFI) and breast cancer-specific survival (BCSS) were assessed in patients stratified by 70-gene signature result (high, low, and ultralow) by Kaplan-Meier analysis and hazard ratios with 95% CI from Cox regression. RESULTS: Median follow-up was 8.7 years. Of the ultralow-risk patients (n = 1,000), 67% were > 50 years, 81% had tumors ≤ 2 cm, 80% were lymph node-negative, 96% had grade 1 or 2 tumors, and 99% were estrogen receptor (ER)-positive. Systemic therapy was received by 84% of patients (69% endocrine therapy, 14% endocrine therapy plus chemotherapy, 1% other) and 16% received no adjuvant systemic treatment. The 8-year DMFI for ultralow-risk patients was 97.0% (95% CI, 95.8 to 98.1), which was 2.5% higher than for patients with low-risk tumors (n = 3,295, 94.5% [95% CI, 93.6 to 95.3]). The hazard ratio for DMFI was 0.65 (95% CI, 0.45 to 0.94) for ultralow versus low risk, after adjusting for clinical-pathologic and treatment characteristics. The 8-year BCSS for ultralow-risk patients was 99.6% (95% CI, 99.1 to 100). CONCLUSION: Patients with an ultralow-risk 70-gene signature have the best prognosis, distinctive from low risk, with 8-year BCSS above 99%, and very few patients developed distant metastases with an 8-year DMFI rate of 97%. These patients could be candidates for further de-escalation of treatment, to avoid overtreatment and the risk of side effects.
引用
- Lopes Cardozo JMN, Drukker CA, Rutgers EJT, et al. Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial. J Clin Oncol. 2022. PMID: 35061525. doi:10.1200/JCO.21.02019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。